SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ)
$41.64 -0.05 (-0.1199%)
Analysed SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) News Sources
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
21-08-2026
yahoo.com
3 Small-Cap Stocks with Open Questions
25-08-2026
yahoo.com
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
31-08-2026
yahoo.com
3 Out-of-Favor Stocks We’re Skeptical Of
02-09-2026
yahoo.com
1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Headwinds
08-09-2026
yahoo.com
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
04-08-2026
yahoo.com
Supernus and Indivior merge to create scaled, CNS-focused entity
04-08-2026
pharmaceutical-technology.com
New Strong Buy Stocks for August 7th
07-08-2026
yahoo.com
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
24-08-2026
yahoo.com
Supernus Pharmaceuticals to Participate in September Investor Conferences
02-09-2026
yahoo.com
What is the current price of SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ)?
The current price of SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) is $41.64.
SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) absolute price change since previous trading day?
The absolute price change of SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) since the previous trading day is $-0.05.
SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) percentage price change since previous trading day?
The percentage price change of SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) since the previous trading day is -0.1199%.
What is the most recent average sentiment score for SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ)?
The most recent average sentiment score for SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ)?
The most recent sentiment for SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ) is .
SEC-8K** Filing Available For SUPERNUS PHARMACEUTICALS INC (SUPN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.